[go: up one dir, main page]

MX2023014683A - Conjugados de anticuerpo anti-egfrviii y farmaco y usos de los mismos. - Google Patents

Conjugados de anticuerpo anti-egfrviii y farmaco y usos de los mismos.

Info

Publication number
MX2023014683A
MX2023014683A MX2023014683A MX2023014683A MX2023014683A MX 2023014683 A MX2023014683 A MX 2023014683A MX 2023014683 A MX2023014683 A MX 2023014683A MX 2023014683 A MX2023014683 A MX 2023014683A MX 2023014683 A MX2023014683 A MX 2023014683A
Authority
MX
Mexico
Prior art keywords
antibodies
drug conjugates
useful
egfrviii
antibody drug
Prior art date
Application number
MX2023014683A
Other languages
English (en)
Inventor
Thomas Nittoli
Jessica Kirshner
Marcus Kelly
Frank Delfino
Gavin Thurston
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023014683A publication Critical patent/MX2023014683A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona conjugados de anticuerpo-fármaco (ADC) que comprenden anticuerpos que se unen a la variante del EGFR de clase III (EGFRvIII) conjugada a tesirina, y los métodos para usarlos. De acuerdo con determinadas modalidades, los anticuerpos o fragmentos de unión a antígeno de los mismos, útiles en la presente descripción, se unen a EGFRvIII humana con alta afinidad. Los anticuerpos o fragmentos de unión a antígeno de los mismos, útiles en la presente descripción, pueden ser anticuerpos completamente humanos. Los ADC proporcionados en la presente descripción son útiles para el tratamiento de diversos cánceres.
MX2023014683A 2021-06-22 2022-06-21 Conjugados de anticuerpo anti-egfrviii y farmaco y usos de los mismos. MX2023014683A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163213478P 2021-06-22 2021-06-22
US202163242929P 2021-09-10 2021-09-10
PCT/US2022/034373 WO2022271722A1 (en) 2021-06-22 2022-06-21 Anti-egfrviii antibody drug conjugates and uses thereof

Publications (1)

Publication Number Publication Date
MX2023014683A true MX2023014683A (es) 2024-01-12

Family

ID=82655068

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014683A MX2023014683A (es) 2021-06-22 2022-06-21 Conjugados de anticuerpo anti-egfrviii y farmaco y usos de los mismos.

Country Status (9)

Country Link
US (1) US20240293566A1 (es)
EP (1) EP4359440A1 (es)
JP (1) JP2024527235A (es)
KR (1) KR20240024061A (es)
AU (1) AU2022298653A1 (es)
CA (1) CA3212850A1 (es)
IL (1) IL309048A (es)
MX (1) MX2023014683A (es)
WO (1) WO2022271722A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250129814A (ko) 2023-01-18 2025-08-29 타이리간드 바이오사이언스 (상하이) 리미티드 항체-약물 접합체 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1991003489A1 (en) 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
PT1392359E (pt) 2001-05-11 2010-01-27 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações
BRPI0411803A (pt) 2003-06-27 2006-05-23 Abgenix Inc anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seus usos
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
TWI513818B (zh) 2009-06-02 2015-12-21 Regeneron Pharma 岩藻糖基化（ｆｕｃｏｓｙｌａｔｉｏｎ）－缺乏之細胞
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
MY178160A (en) 2014-03-11 2020-10-06 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
KR20230035690A (ko) * 2016-06-08 2023-03-14 애브비 인코포레이티드 항-egfr 항체 약물 콘쥬게이트
CN109562190A (zh) * 2016-06-08 2019-04-02 艾伯维公司 抗egfr抗体药物偶联物

Also Published As

Publication number Publication date
AU2022298653A9 (en) 2023-10-19
IL309048A (en) 2024-02-01
US20240293566A1 (en) 2024-09-05
WO2022271722A1 (en) 2022-12-29
JP2024527235A (ja) 2024-07-24
AU2022298653A1 (en) 2023-10-12
EP4359440A1 (en) 2024-05-01
CA3212850A1 (en) 2022-12-29
KR20240024061A (ko) 2024-02-23

Similar Documents

Publication Publication Date Title
MX2024011292A (es) Conjugados de camptotecina.
MY179851A (en) Anti-prlr antibodies and uses thereof
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
MX2022005221A (es) Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso.
MX2023004434A (es) Anticuerpos anti-fgfr2 y metodos para usarlos.
SA523442921B1 (ar) جزيئات ربط علاجية
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
MX2023013995A (es) Conjugados de anticuerpo y antraciclina.
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2021010453A (es) Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos.
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
PH12021552379A1 (en) Anti-egfrviii antibodies and antigen-binding fragments thereof
WO2022034524A3 (en) Antibodies against ilt2 and use thereof
MX2025005811A (es) Conjugados de anticuerpo ceacam5-fármaco y métodos de uso de los mismos
MX2025006057A (es) Conjugados anticuerpo-farmaco anti-cea y metodos de uso
SA520420225B1 (ar) cMET مترافقات عقار من عوامل رابطة أحادية النسيلة من واستخداماتها
MX2025003663A (es) Anticuerpos anti-napi2b y metodos de uso
PH12023550745A1 (en) Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
MX2023014683A (es) Conjugados de anticuerpo anti-egfrviii y farmaco y usos de los mismos.
MX2020002266A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos.
GEAP202516711A (en) Anti-monomethyl auristatin antibodies and antibody fragments
MX2024007035A (es) Anticuerpos anti-cdh6 y conjugados anticuerpo-farmaco de los mismos.
MX2025007664A (es) Conjugados de anticuerpos farmacos b7h3
MX2025004144A (es) Anticuerpo anti-gucy2c y usos del mismo